Clinical experience of using zonisamide in structural focal epilepsy in children with cerebral palsy

3Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

Abstract

Objective. To evaluate the efficacy and safety of zonisamide as an add-on therapy in structural focal epilepsy in children with cerebral palsy (CP). Material and methods. Sixty-four patients (36 boys and 28 girls) with spastic CP and structural focal epilepsy with refractory seizures were followed up. Patients received zonisamide in a dose of 6—8.8 mg/kg/day for ≥6 months. Treatment efficacy was assessed by the reduction of seizures depending on CP form, type of epileptic seizures, combination of zonisamide with other drugs and adverse-effects. Results and conclusion. A reduction of seizures by ≥50% was identified in 60.9% of children, 10.9% showed a better recovery. The best efficacy (35.9%) was demonstrated in the treatment of generalized seizures with focal onset and in the combination with levetiracetam (35.9%). Adverse effects of mild to moderate severity were noted in 26.5% of children. The treatment was discontinued in 7.8%. Therefore, zonisamide is an effective treatment for refractory structural focal epilepsy in children with CP and comorbid pathology, which reduces the frequency of seizures without severe side-effects.

Cite

CITATION STYLE

APA

Badalyan, O. L., Trepilets, V. M., & Trepilets, S. V. (2018). Clinical experience of using zonisamide in structural focal epilepsy in children with cerebral palsy. Zhurnal Nevrologii i Psihiatrii Imeni S.S. Korsakova, 118(10), 90–97. https://doi.org/10.17116/jnevro201811810290

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free